VSIR (PMC-309 Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA884484MB3HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
VSIR antibody; C10orf54 antibody; SISP1 antibody; VISTA antibody; PP2135 antibody; UNQ730/PRO1412 antibody; V-type immunoglobulin domain-containing suppressor of T-cell activation antibody; Platelet receptor Gi24 antibody; Stress-induced secreted protein-1 antibody; Sisp-1 antibody; V-set domain-containing immunoregulatory receptor antibody; V-set immunoregulatory receptor antibody
Species Reactivity
Human
Immunogen
Recombinant Human VSIR protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is a research-grade biosimilar to PMC-309, designed to specifically target VSIR (V-Set Immunoregulatory Receptor), also known as VISTA, B7-H5, or C10orf54. VSIR functions as an immune checkpoint protein expressed on hematopoietic cells, particularly myeloid cells and T lymphocytes, where it delivers inhibitory signals that suppress T cell activation and proliferation. This receptor plays a critical role in maintaining immune homeostasis and preventing excessive inflammatory responses. Dysregulation of VSIR has been implicated in various pathological conditions, including cancer immune evasion, autoimmune diseases, and chronic inflammatory disorders, making it an important therapeutic target for immunomodulation research.

PMC-309 represents a reference antibody used extensively in preclinical studies investigating VSIR-mediated immune regulation and checkpoint blockade mechanisms. This biosimilar provides researchers with a reliable tool for exploring VSIR's role in tumor microenvironments, studying immune cell interactions, and evaluating potential immunotherapeutic strategies. The antibody supports investigations into cancer immunology, transplant tolerance, and inflammatory disease models, enabling detailed characterization of VSIR expression patterns and functional consequences across diverse experimental systems.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Immunoregulatory receptor which inhibits the T-cell response. May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling. May stimulate MMP14-mediated MMP2 activation.
Gene References into Functions
  1. Data indicate that VISTA is predominantly expressed and up-regulated in the high-density infiltrated immune cells but minimal in pancreatic cancerous cells. PMID: 29771768
  2. High VISTA expression is associated with colorectal carcinoma. PMID: 30128738
  3. VISTA expression supports immune-complex inflammation in collagen antibody-induced arthritis and VISTA is expressed in human synovium PMID: 29216931
  4. This study is the first to describe the expression of VISTA-expressing lymphocytes in melanoma samples and in the context of acquired resistance to immune checkpoint inhibitors PMID: 28776578
  5. Taken together, the results indicated that the VISTA high and CD8 low group, as an immunosuppressive subgroup, might be associated with a poor prognosis in primary OSCC. These findings indicated that VISTA might be a potential immunotherapeutic target in OSCC treatment. PMID: 28236118
  6. this review describes the functions of VISTA in the context of cancer immunotherapy PMID: 28258694
  7. overexpression of the newly described co-stimulatory molecule, PD1 homologue (PD-1H) in human monocyte/macrophages is sufficient to induce spontaneous secretion of multiple cytokines. PMID: 25279955
  8. p53-induced expression of DD1alpha prevents persistence of cell corpses and ensures efficient generation of precise immune responses in mice. PMID: 26228159
  9. Results suggest that GI24 contributes to tumor-invasive growth in the collagen matrix by augmenting cell surface MT1-MMP. PMID: 20666777

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein.
Tissue Specificity
Expressed in spleen. Detected on a number of myeloid cells including CD11b monocytes, CD66b+ neutrophils, at low levels on CD4+ and CD8+ T-cells, and in a subset of NK cells. Not detected on B cells (at protein level). Expressed at high levels in placenta
Database Links

HGNC: 30085

OMIM: 615608

KEGG: hsa:64115

STRING: 9606.ENSP00000378409

UniGene: Hs.47382

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*